New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback